The goal of this study is to evaluate if indocyanine green (ICG) fluorescence imaging helps reduce complications in bowel surgery performed during gynecologic cancer operations.
The main question it aims to answer is: Does using ICG fluorescence imaging during bowel anastomosis reduce the rate of complications such as leaks, infections, and abscesses within 30 days after surgery? Participants are women aged 18 and older undergoing surgery for gynecologic cancers (such as ovarian, uterine, cervical, or vulvar cancer). During surgery, investigators will inject ICG intravenously, then use a special near-infrared camera to see how well blood flows at the anastomosis site. The investigators will then decide if the reconnection is good enough or needs adjustment.
Researchers will record any complications within the first 30 days after surgery to understand if this imaging method helps reduce surgical risks.

Start Date01 Sep 2025

Sponsor / Collaborator

Istanbul University

NCT06672224

/ Not yet recruitingNot ApplicableIIT

Prospective Analysis of Patients at Risk for Breast Cancer-Related Lymphedema (BCRL) Using Indocyanine Green (ICG) Fluoroscopy and SPYTM Angiography

This clinical trial assesses the change in lymphatic structure from placement of an intravenous (IV) line and fluid administration using a diagnostic agent, indocyanine green (ICG), with SPY (Trademark) angiography in breast cancer patients at risk for breast cancer-related lymphedema (BCRL). Patients that are diagnosed with breast cancer with lymph node involvement often undergo treatment that includes surgery to remove the axillary nodes and radiation. Unfortunately, this procedure increases the incidence of BCRL in the surgical arm, as well as other problems including heaviness of the arm, fibrotic skin changes, and an increase in infection risk. Because of these symptoms, venipuncture (blood draw) is often avoided in these arms. Researchers want to show that placement of an IV line and fluid administration in patients at risk for BCRL will indeed not alter the lymphatic structure of the arm and will not change the incidence of BCRL by administering indocyanine green (ICG) dye to patients and assessing their arm lymphatics. ICG is a fluorescent dye that is able to be visualized by the SPY angiography imaging system as it travels through the lymphatic system, allowing researchers to assess how well blood flows throughout the body. Receiving ICG and undergoing SPY angiography may be effective in showing that placement of an IV and fluid administration in breast cancer patients at risk for BCRL will not alter the lymphatic structure of their arm and will not change the incidence of BCRL.

Start Date14 Aug 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT06867978

/ Not yet recruitingPhase 1

A Prospective, Multi-Center, Assessor-Blinded Study on the Clinical Efficacy of CCeLL-In Vivo (Confocal Fluorescence Endomicroscopy) for Intraoperative Brain Tumor Diagnosis.

The primary objective of this study is to demonstrate the non-inferiority of cCeLL compared to frozen section analysis. The investigational device is intended for use with indocyanine green (ICG) for fluorescence imaging as an aid in the visualization of vessels (micro- and macro-vasculature) blood flow in the cerebrovascular before, during or after cranial diagnostic and therapeutic procedures, such as tumor biopsy and resection, which is then read and analyzed by trained-professional for intraoperative diagnosis. The comparison will be held by the device with the conventional intraoperative histological frozen section analysis of identical brain tissue samples in the same patient. Both methods will be compared in terms of their accuracy using the standard of practice, the final pathological diagnosis.

Start Date01 Jun 2025

Sponsor / Collaborator

Vpix Medical, Inc.

100 Clinical Results associated with Indocyanine Green

100 Translational Medicine associated with Indocyanine Green

100 Patents (Medical) associated with Indocyanine Green

7,579

Literatures (Medical) associated with Indocyanine Green

01 Dec 2025·Journal of Gastrointestinal Cancer

Initial Application of Fluorescence Imaging for Intraoperative Localization of Small Neuroendocrine Tumors in the Pancreas: Case Report and Review of the Literature

Review

Author: Fang, Xiaosan ; Qian, Daohai ; Shen, Zhengchao ; Zheng, Xingyuan ; Xi, Shihang ; Muhammad, Danish Irshad ; Wang, Xiaoming ; Wang, Guannan ; Wang, Xu ; Jiang, Bin ; Jiang, Yaqi

BACKGROUNDIndocyanine green is commonly used for laparoscopic hepatectomy but remains uncommon in pancreatic surgery. Given the increasing number of small neuroendocrine tumors found in the pancreas and the heavy reliance on laparoscopic ultrasound for intraoperative localization, we attempted to use indocyanine green for these tumors. Our results show good localization and have the potential to provide a valuable clinical aid.CASE PRESENTATIONThis case report details five patients with preoperative diagnosis of pancreatic neuroendocrine tumors of small endocrine tumors, intraoperative successful localization, and successful completion of laparoscopic partial resection of pancreatic tumors by indocyanine green fluorescence staining; none of the patients experienced serious complications after surgery and were discharged from the hospital, and routine pathology confirmed that four cases were pancreatic neuroendocrine tumors of G1 stage, and one case was pancreatic neuroendocrine cell hyperplasia.CONCLUSIONFluorescence imaging technology safely aids in the intraoperative localization of small pancreatic neuroendocrine tumors.

01 Jun 2025·Biomaterials

A mitochondria-interfering nanocomplex cooperates with photodynamic therapy to boost antitumor immunity

Article

Author: Deng, Qingyuan ; Wang, Xing ; Zhao, Qingfu ; Yang, Xiangliang ; Xu, Qingqing ; Hua, Ao ; Li, Zifu ; Zhang, Zhijie

Immunotherapeutics against triple-negative breast cancer (TNBC) hold great promise. In this work, we provide a combination therapy for simultaneous increasing tumor immunogenicity and down-regulating programmed cell death ligand 1 (PD-L1) to boost antitumor immunity in TNBC. We prepare bis (diethyldithiocarbamate)-copper/indocyanine green nanoparticles (CuET/ICG NPs) simply in aqueous with one-pot method. CuET/ICG NPs interfere mitochondria, reduce oxygen consumption, and alleviate tumor hypoxia to potentiate photodynamic therapy (PDT) for amplifying immunogenic cell death (ICD). Meanwhile, mitochondria dysfunction leads to energy stress and activates AMPK pathway. As a result, CuET/ICG NPs downregulates membrane PD-L1 (mPD-L1) on both 4T1 cancer cells and cancer stem cells (CSCs) through AMP-activated protein kinase (AMPK)-mediated pathway in hypoxia. Cooperatively, the combinational therapy activates antitumor immunity and triggers long lasting immune memory response to resist tumor re-challenge. Our study represents an attempt that conquers tumor immunosuppressive microenvironment with simple biomedical materials and multimodality treatments.

01 Jun 2025·Biomaterials

Molecularly manipulating pyrazinoquinoxaline derivatives to construct NIR-II AIEgens for multimodal phototheranostics of breast cancer bone metastases

Article

Author: Liu, Yi ; Zhu, Jun ; Wang, Lei ; Wang, Dong ; Yan, Xueke ; Tang, Ben Zhong ; Su, Huifang ; Zheng, Ping

Multimodal phototheranostics on the basis of single molecular species shows inexhaustible and vigorous vitality, particularly those emit fluorescence in the second near-infrared window (NIR-II), the construction of such exceptional molecules nonetheless retains formidably challenging. In view of the undiversified molecular skeletons and insufficient phototheranostic outputs of previously reported NIR-II fluorophores, herein, electron acceptor engineering based on heteroatom-inserted rigid-planar pyrazinoquinoxaline was manipulated to fabricate aggregation-induced emission (AIE)-featured NIR-II counterparts with donor-acceptor-donor (D-A-D) architecture. Systematical investigations substantiated that one of those synthesized AIE molecules, namely 4TPQ, incorporating a fused thiophene acceptor, synchronously exhibited high molar absorptivity (ε), NIR-II emission, typical AIE tendency, significant reactive oxygen species (ROS) generation, and high photothermal conversion efficiency. These extraordinary behaviors endowed 4TPQ nanoparticles with unprecedented performance on NIR-II fluorescence/photothermal imaging-navigated synergistic photodynamic/photothermal inhibition of tumors, as confirmed by the mice model of breast cancer bone metastases. This study thus brings significant insights into developing phototheranostic systems for clinical trials.

News (Medical) associated with Indocyanine Green

13 Nov 2024

·www.businesswire.com

Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial Evaluating Potential of Abenacianine for Injection (VGT-309) to Improve Tumor Visualization During Cancer Surgery

MINNEAPOLIS--( BUSINESS WIRE )-- Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced completion of patient enrollment in the company’s Phase 2, multi-center VISUALIZE trial, evaluating the efficacy and safety of abenacianine for injection (VGT-309) in patients with cancer in the lung. Abenacianine for injection is a novel, investigational tumor-targeted fluorescent imaging agent designed to improve the visibility of difficult-to-find and previously undetected tumors during minimally invasive and robotic-assisted surgical procedures. “The VISUALIZE trial will provide additional, valuable insights illuminating the potential of our novel imaging agent to address existing deficits in tumor visualization during lung surgery,” said John Santini, Ph.D., president and chief executive officer at Vergent Bioscience. “Completing enrollment in the trial is an exciting milestone that reflects our team’s dedication, as well as the commitment of the VISUALIZE clinical investigators and study participants. We look forward to sharing the results of this study.” Data from previous clinical studies of abenacianine for injection suggest the agent allowed surgeons to see tumor tissue during minimally invasive surgery (MIS), including robotic-assisted surgical procedures, providing “molecular sight” and potentially increasing their confidence in MIS. For the Phase 2 VISUALIZE trial, investigators at six sites in the United States and Australia enrolled 89 patients with cancer in the lung, all of whom received 0.32mg/kg abenacianine for injection as a short infusion 12 to 36 hours prior to surgery. Following data readout from the VISUALIZE trial, Vergent intends to advance the agent into a Phase 3 study. Assuming positive Phase 3 results, the company will file a new drug application (NDA) for abenacianine for injection for cancer in the lung. About Lung Cancer Surgery Approximately 25% of all U.S. lung cancer patients undergo lung cancer surgery, which can be a curative treatment if lung cancer is diagnosed early, and all tumor tissue is removed. 1 MIS and robotic-assisted surgery methods are increasingly utilized in lung cancer resection because these approaches are associated with shorter hospital stays, smaller incisions, less blood less, and decreased post-operative complications. While these are important advantages, MIS and robotic-assisted surgery often compromise surgeons’ sight and ability to feel tissue during procedures, making it difficult for them to distinguish tumors from normal tissue and ensure all tumor tissue is removed. About the VISUALIZE Clinical Trial The Phase 2, multi-center, open-label VISUALIZE study ( NCT06145048 ) was designed to evaluate the efficacy and safety of abenacianine for injection in patients undergoing surgery for proven or suspected cancer in the lung. Each of the 89 patients in the study received 0.32mg/kg abenacianine for injection 12 to 36 hours prior to surgery. Following an attempt to identify each tumor using standard surgical techniques, investigators used a commercially available near-infrared (NIR) endoscope to assess the presence of tumor tissue, which was then confirmed by pathology. Primary efficacy endpoints included visualization of tumors intraoperatively, surgical margin assessment, and identification of additional cancers or positive lymph nodes that may not have been seen preoperatively. About Abenacianine for Injection (VGT-309) Abenacianine for injection is a tumor-targeted fluorescent imaging agent designed to enable a complete solution for optimal tumor visualization during open, minimally invasive and robotic-assisted surgical procedures. Abenacianine for injection is delivered to patients via a short intravenous infusion several hours before surgery. Invented in Professor Matt Bogyo’s Lab at Stanford University School of Medicine, the molecule binds tightly (i.e., covalently) to cathepsins, a family of proteases that are overexpressed across a broad range of solid tumors. This approach, if successful, would provide distinct clinical advantages and position abenacianine for injection as an ideal tumor imaging agent. Abenacianine for injection’s imaging component is the near infrared (NIR) dye indocyanine green (ICG), which is compatible with all commercially available NIR intraoperative imaging systems that support MIS technologies and is a preferred dye to minimize confounding background autofluorescence. About Vergent Bioscience, Inc. Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by improving the visibility of tumors. Vergent’s lead compound, abenacianine for injection, is a tumor-targeted fluorescent imaging agent designed to enable surgeons to see difficult-to-find or previously undetected tumors in real-time during surgery, so that they can ensure all tumor tissue is removed. The company is first evaluating abenacianine for injection for cancer in the lung, with the potential to expand its application to a wide range of solid tumors. Vergent Bioscience is a privately held company based in Minneapolis, MN. Lu T, et al. "Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades," Cancer Manag Res. 2019 Jan 21;11:943-953. https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/30718965/

Phase 2Clinical ResultPhase 3

18 Jul 2024

·www.businesswire.com

Vergent Bioscience Data Published in The Annals of Thoracic Surgery Demonstrate VGT-309 May Help Surgeons Visualize Tumor Tissue in the Lung During Surgery

MINNEAPOLIS--( BUSINESS WIRE )-- Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that data published in The Annals of Thoracic Surgery reinforce the clinical potential of VGT-309, the company’s investigational intraoperative molecular imaging (IMI) agent, to help surgeons see difficult-to-find and previously undetected tumors in the lung during surgery. The findings support previous clinical trial results suggesting that VGT-309 could help ensure all tumor tissue is removed during minimally invasive and robotic-assisted surgical procedures. “The expanded use of minimally invasive surgery, including robotic-assisted technologies, for lung cancer has created a significant and growing need for better visualization during these surgeries, which can be curative when lung cancer is diagnosed early enough and all tumor tissue is removed,” said John Santini, Ph.D., president and chief executive officer at Vergent Bioscience. “We are pleased that data from our clinical program continue to suggest VGT-309 may help overcome existing challenges to tumor visualization and thereby optimize surgical outcomes for physicians and patients.” The Phase 2* efficacy study evaluated the frequency that IMI with VGT-309 improved surgical outcomes in 40 individuals with suspected or proven cancer in the lung who were eligible for surgery. The primary efficacy endpoint was the proportion of patients with at least one clinically significant event. Clinically significant events were defined as localization of lesions not found by standard surgical techniques, identification of synchronous and occult cancers, and identification of inadequate surgical margin. Each patient in the study received VGT-309 preoperatively through intravenous infusion. Following an attempt to localize the target lesion using standard surgical techniques, investigators used a commercially available near infrared (NIR) endoscope to visualize the lesion, which was then assessed by pathology. Of the 40 participants administered VGT-309 who underwent the standard-of-care surgical resection for suspected lung cancer, 17 (42.5%) had at least one clinically significant event. VGT-309 with NIR fluorescence imaging visualized a range of primary and metastatic tumor types intraoperatively, including adenocarcinoma in situ, invasive adenocarcinoma, lymphoma, colorectal cancer, neuroendocrine tumors, sarcomas, and squamous cell carcinoma. VGT-309 appeared safe and well tolerated in this study, with no infusion reactions and no drug-related serious adverse events. “While the prevalence of minimally invasive surgery has increased over the years, these surgical approaches require surgeons to work in a small area with a restricted view and limited tactile clues, increasing the possibility that tumor tissue will be difficult to locate or even missed,” said study investigator and senior author Sunil Singhal, M.D., chief of the Division of Thoracic Surgery in the Perelman School of Medicine at University of Pennsylvania. “The study findings published today in The Annals of Thoracic Surgery add to the growing body of evidence suggesting that VGT-309 has the potential to provide meaningful benefit to both surgeons and cancer patients during minimally invasive surgery.” To further evaluate the efficacy of VGT-309, Vergent is currently conducting the Phase 2 multicenter VISUALIZE study ( NCT06145048) . Investigators at six sites in the United States and Australia plan to enroll 100 patients in this Phase 2 study, which Vergent expects to complete by the end of 2024. *This clinical trial ( ClinicalTrials.gov Identifier: NCT05400226) was supported by the National Cancer Institute of the National Institutes of Health under award number R44CA277890. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About VGT-309 VGT-309 is a tumor-targeted fluorescent imaging agent designed to enable a complete solution for optimal tumor visualization during open, minimally invasive and robotic-assisted surgical procedures. VGT-309 is delivered to patients via a short intravenous infusion several hours before surgery. Invented in Professor Matt Bogyo’s Lab at Stanford University School of Medicine, the molecule binds tightly (i.e., covalently) to cathepsins, a family of proteases that are overexpressed across a broad range of solid tumors. This approach, if successful, provides distinct clinical advantages and positions VGT-309 as an ideal tumor imaging agent. VGT-309’s imaging component is the near infrared (NIR) dye indocyanine green (ICG), which is compatible with all commercially available NIR intraoperative imaging systems that support MIS technologies and is a preferred dye to minimize confounding background autofluorescence. About Vergent Bioscience, Inc. Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent designed to enable surgeons to see difficult-to-find or previously undetected tumors in real-time during surgery, so that they can ensure all tumor tissue is removed. The company is first evaluating VGT-309 for cancer in the lung, with the potential to expand its application to a wide range of solid tumors. Vergent Bioscience is a privately held company based in Minneapolis, MN.

Clinical ResultPhase 2

12 Feb 2024

·www.fiercebiotech.com

CMR Surgical adds new tissue imaging tech to Versius robot

CMR Surgical's vLimeLite system will first be installed at Gloucestershire Royal Hospitals NHS Trust in the U.K. for use in upper gastrointestinal surgery procedures. CMR Surgical is launching a new imaging technology to help users of its Versius robot visualize the flow of blood through organs during a procedure. The company’s vLimeLite add-on incorporates a near-infrared fluorescent light that reacts with the injectable medical dye indocyanine green, known as ICG. The CE-marked system aims to highlight blood vessels and tissue perfusion beyond the naked eye, as well as the body’s bile duct anatomy. “This is the most significant update of Versius since it launched back in 2019,” CEO Supratim Bose said in the company’s announcement. “We have listened to the needs of surgeons, and I’m delighted that we have been able to give them what they want—a best-in-class ICG product that we know will make a real difference for their patients.” The system will first be installed at Gloucestershire Royal Hospitals NHS Trust in the U.K. for use in upper gastrointestinal surgery procedures. CMR said it plans to roll out vLimeLite first in the U.K., Ireland and Hong Kong before obtaining additional regulatory approvals and expanding globally over the course of this year. vLimeLite will launch with video overlays that integrate with Versius’ 3D vision and will allow the surgeon to toggle between green, cyan and grayscale ICG viewing modes. “I think what is really special is the overlay mode option, which means Versius surgeons will be able to use our integrated ICG system while continuing to view in full color with the same video quality,” said Mark Slack, CMR co-founder and chief medical officer. “vLimeLite truly allows surgeons to see what was once invisible to them.” In January, CMR reported what it described as its strongest quarter on record, in terms of system placements and procedures performed. Over the course of the full 12 months of 2023, the company said its install base grew 50% over 2022’s tally, with surgery counts growing more than 60% to a total of more than 17,000 since Versius’ launch. The numbers follow expansions in Europe, Asia, the Middle East, Africa and Latin America. The company also said it plans to launch new instrumentation options and digital software for Versius in 2024. Late last year, CMR opened a new manufacturing facility near its home in Cambridge, U.K., that it says has the capacity to produce up to 500 Versius systems per year.

100 Deals associated with Indocyanine Green

External Link

KEGG	Wiki	ATC	Drug Bank
D01342	Indocyanine Green	V04CX01	DB09374

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bile Duct Diseases	United States	Novadaq Technologies ULC	21 Nov 2018
Uterine Cervical Cancer	United States	Novadaq Technologies ULC	21 Nov 2018
Uterine Neoplasms	United States	Novadaq Technologies ULC	21 Nov 2018
Vascular Diseases	United States	Novadaq Technologies ULC	21 Nov 2018
Breast Cancer	Japan	Daiichi Sankyo Co., Ltd.	18 Sep 2009
Melanoma	Japan	Daiichi Sankyo Co., Ltd.	18 Sep 2009
Contrast agents	Japan	Santen Pharmaceutical Co., Ltd.	11 Apr 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Colonic Cancer	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Esophageal Carcinoma	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Non-Small Cell Lung Cancer	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Thymoma	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Thyroid Cancer	Phase 2	United States	University of Pennsylvania	14 Aug 2024
Head and Neck Neoplasms	Phase 2	United States	Tactile Systems Technology, Inc.	01 Oct 2016
liver function failure	Phase 2	United States	CardioX, Inc.	01 Nov 2015
Central Nervous System Neoplasms	Phase 2	United States	Abramson Cancer Center	10 Jun 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04534816 (Pubmed \| Int J Surg)	Not Applicable	Wounds, Penetrating	-	Indocyanine green (ICG-FA)	(xdwgmhtfdq) = jnijdvgixm pspqvqtwsj (daoxzdrsuo ) View more	Positive	01 Dec 2024
NCT04534816 (Pubmed \| Int J Surg)	Not Applicable	Wounds, Penetrating	-	Indocyanine green (Control (no ICG-FA))	ulapbwelxj(lbcwpisbpz) = klhnumqglk ioasirwfas (mivhyutyxj ) View more	Positive	01 Dec 2024
EURETINA2024	Not Applicable	Retinoblastoma	-	Indocyanine Green (TTT alone)	bhwvjuhoyt(exkjbohxcz) = rdhsbjxstq kjclljgsrz (bmicphqdho )	Positive	19 Sep 2024
EURETINA2024	Not Applicable	Retinoblastoma	-	Indocyanine Green (ICG enhanced TTT)	ourljtxeyo(rmvgblqmcl) = decgdsqepi comvyazusm (smqjsxgsgz ) View more	Positive	19 Sep 2024
WCLC2024	Not Applicable	Bronchopneumonia	-	Indocyanine Green (Mesh nebulizer)	(krnenitwmx) = no adverse events were recorded twnfmrilxb (rpqetagmkl ) View more	-	07 Sep 2024
NCT01034670 (CTgov)	Not Applicable	Gastrointestinal Stromal Tumors \| Stomach Cancer	3	fluorescent Peptide+indocyanine green	ppojpjtybh(awcncshxpk) = dpamuutlvu wifwivecxf (ccpjycoqmx, jmxhhkjqoh - lshskhobef) View more	-	26 Jun 2024
NCT05094102 (CTgov)	Not Applicable	Breast Cancer \| Lymphedema	9	OnLume Imaging System+Indocyanine green	xxhspfyaqr(gfwzuvjmur) = oetcakzaaz rzocrhyzhy (cvekbbjunj, cgigigxzvc - odcwvjfaac) View more	-	23 May 2024
AHNS2024	Not Applicable	-	-	ICG injection	yuiurhwxlq(gcjwbifwdw) = vvehxxpmvp wgqbquewpz (ywomlycxmo, 63.1 - 100) View more	-	15 May 2024
MP61-16 (AUA2024)	Not Applicable	Squamous Cell Carcinoma of the Penis	12	Indocyanine Green (Inguinal lymph-node dissection (ILND))	shsvivuyjs(ahpuvqofiz) = Postoperative complications were recorded in 8 out of 16 procedures, with a low rate of wound dehiscence and no flap necrosis observed itsshhiipk (orcsaggdiu )	Positive	01 May 2024
MP61-16 (AUA2024)	Not Applicable	Squamous Cell Carcinoma of the Penis	12	Indocyanine Green (Inguino-pelvic lymph-node dissection (IPLND))		Positive	01 May 2024
902 (ESGO2024)	Not Applicable	Endometrial Carcinoma	22	Indocyanine green (ICG)	qkcscyykzq(ebcycsttfr) = There were no allergic reactions to the ICG lcsvlmgobs (frnffylrmz )	Positive	10 Mar 2024
ESMO2023	Not Applicable	Breast Cancer	69	indocyanine green (ICG and RI)	xwdfeotjwl(kbafxynpuc) = rrxeijqssb thfmbpewvg (xfuwexpiem ) View more	-	21 Oct 2023
ESMO2023	Not Applicable	Breast Cancer	69	indocyanine green (Blue dye and RI)	lsbrcwfous(rkgqxkfiuz) = zmursapzop zsqtedcbxx (ceouvmphdc, 94.3 - 99.1)	-	21 Oct 2023
NCT04511026 (CTgov)	Phase 2	Endometrial Carcinoma	6	Single Photon Emission Computed Tomography (SPECT)+Lymphoseek+Indocyanine Green (ICG)	dhaybxcjnf(uvppsevskq) = ulzjydqivg evlixiotyu (pxzjzjdgak, mefwdegbtg - njyiuqlfzx) View more	-	11 Oct 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis